Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01025492 · ClinicalTrials.gov registry record · Phase 4
Study of Trilipix Effects on Lipids and Arteries
A Phase 4 study, sponsored by University of Utah.
- Terminated
- Registry status
- Phase 4
- Development phase
- 24
- Enrollment target
NCT01025492 is a Phase 4 study that was terminated before completion, run by University of Utah. The registered enrollment target is 24 participants.
The verdict
NCT01025492, a Phase 4 study, was terminated before completion, sponsored by University of Utah.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 24 participants
- Enrollment target
Study Summary
Fibrates reduce atherosclerosis and cardiovascular disease events. A major mechanism of this benefit appears to be their ability to raise plasma high density lipoprotein cholesterol (HDL-C), especially in patients with high triglyceride levels. This study will investigate the effects of the addition of Trilipix (fenofibric acid) versus placebo to ongoing statin treatment on high density lipoprotein (HDL) composition and arterial function in subjects with insulin resistance.
Interventions
- DRUG placebo
- DRUG Trilipix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2009-11 |
| Est. Completion | 2011-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01025492
The ClinicalTrials.gov registry entry for NCT01025492 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01025492 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01025492 about?
NCT01025492 is a clinical study titled "Study of Trilipix Effects on Lipids and Arteries". Fibrates reduce atherosclerosis and cardiovascular disease events. A major mechanism of this benefit appears to be their ability to raise plasma high density lipoprotein cholesterol (HDL-C), especially in patients with high triglyceride levels. This study will investigate the effects of the addition...
What is the current status of trial NCT01025492?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 24 participants. The study started on 2009-11. Estimated completion is 2011-03.
What interventions are being tested in trial NCT01025492?
The interventions under investigation include: placebo (DRUG), Trilipix (DRUG).
Who is sponsoring clinical trial NCT01025492?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.